XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements
9 Months Ended
May 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Note 8 – Fair Value Measurements

The following table presents the Company’s financial assets and liabilities measured at fair value, based upon the level within the fair value hierarchy in which the fair value measurements fall, as of May 31, 2024, May 31, 2023, and August 31, 2023. There were no transfers between any levels for the periods presented.

 

 

May 31, 2024

 

($ in thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash and cash equivalents

 

$

140,221

 

 

$

 

 

$

 

 

$

140,221

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds

 

 

 

 

 

10,086

 

 

 

 

 

 

10,086

 

U.S. treasury securities

 

 

 

 

 

2,411

 

 

 

 

 

 

2,411

 

Derivative assets

 

 

 

 

 

1,380

 

 

 

 

 

 

1,380

 

Derivative liabilities

 

 

 

 

 

(460

)

 

 

 

 

 

(460

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

May 31, 2023

 

($ in thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash and cash equivalents

 

 

131,577

 

 

 

 

 

 

 

 

 

131,577

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds

 

 

 

 

 

11,360

 

 

 

 

 

 

11,360

 

U.S. treasury securities

 

 

 

 

 

1,446

 

 

 

 

 

 

1,446

 

Derivative assets

 

 

 

 

 

2,817

 

 

 

 

 

 

2,817

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

August 31, 2023

 

($ in thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash and cash equivalents

 

$

160,755

 

 

$

 

 

$

 

 

$

160,755

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds

 

 

 

 

 

4,095

 

 

 

 

 

 

4,095

 

U.S. treasury securities

 

 

 

 

 

1,461

 

 

 

 

 

 

1,461

 

Derivative assets

 

 

 

 

 

1,672

 

 

 

 

 

 

1,672

 

Derivative liabilities

 

 

 

 

 

(457

)

 

 

 

 

 

(457

)

 

 

The Company’s investment in marketable securities consists of corporate bonds and United States treasury bonds. The marketable securities are classified as available-for-sale and are carried at fair value with the change in unrealized gains and losses reported as a separate component on the condensed consolidated statements of comprehensive income until realized. The Company determines fair value using data points that are observable, such as quoted prices and interest rates. The amortized cost of the investments approximates fair value. Investment income is recorded within other income (expense) on the condensed consolidated statements of earnings. As of May 31, 2024, all of the Company’s marketable securities investments mature within one year.

 

The Company enters into derivative instrument agreements to manage risk in connection with changes in foreign currency. The Company only enters into derivative instrument agreements with counterparties who have highly rated credit and does not enter into derivative instrument agreements for trading or speculative purposes. The fair values are based on inputs other than quoted prices that are observable for the asset or liability and are determined by standard calculations and models that use readily observable market parameters. These inputs include foreign currency exchange rates and interest rates. Industry standard data providers are the primary source for forward and spot rate information for both interest rates and foreign currency exchange rates.

The Company has entered into various cross currency swaps that mature between the second quarter of fiscal 2026 and the third quarter of fiscal 2027 with a total notional amount of $100.0 million, or €91.7 million. The Company elected the spot method for designating these swaps as net investment hedges. Changes in the fair value of these contracts are reported in accumulated other comprehensive loss on the condensed consolidated balance sheets and the fair value of these contracts is recorded within other noncurrent assets and other noncurrent liabilities on the condensed consolidated balance sheets. The fair value of these contracts as of May 31, 2024 is included in the table above as either derivative assets or liabilities.

 

At May 31, 2024 the Company had an outstanding foreign currency forward contract to sell a notional amount of 190.9 million South African rand at fixed prices to settle during the Company's next fiscal quarter ending August 31, 2024. The Company’s foreign currency forward contract does not qualify as a hedge of a net investment in foreign operations. The fair value of this contract as of May 31, 2024 is recorded within other current assets on the condensed consolidated balance sheets.

 

 

There were no required fair value adjustments for assets and liabilities measured at fair value on a non-recurring basis for the nine months ended May 31, 2024 or 2023.